Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tris Pharma Starts ALLEVIATE-1 and 2 Trials of Cebranopadol for Pain Treatment
Details : TRN-228 (cebranopadol) is a first-in-class therapy, with a novel mechanism of action that targets both NOP and MOP receptor, called dual-NMR agonist for the treatment of multiple types of pain.
Brand Name : TRN-228
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 21, 2024
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cebranopadol
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : National Institute on Drug Abuse
Deal Size : $16.6 million
Deal Type : Funding
Details : Funding will support the studies of Cebranopadol, the first and only full, dual NOP/MOP receptor agonist and has demonstrated reduced cocaine and heroin self-administration and drug-seeking behaviors, reinforcing its potential as an effective treatment f...
Brand Name : TRN-228
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 28, 2023
Lead Product(s) : Cebranopadol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : National Institute on Drug Abuse
Deal Size : $16.6 million
Deal Type : Funding
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Cebranopadol is a novel, dual nociceptin/orphanin FQ peptide (NOP) receptor and μ-opioid peptide (MOP) receptor agonist in development for the treatment of moderate to severe pain.
Brand Name : TRN-228
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 13, 2022
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Tris Pharma Inc
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Park Therapeutics is developing a unique, first-in-class, investigational NCE for the treatment of pain which is Phase III-ready. With the acquisition, Tris owns worldwide rights and all accompanying intellectual property for cebranopadol.
Brand Name : PRK-101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 29, 2021
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Tris Pharma Inc
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?